L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs , with EC 50 s of 0.13, 0.29, 1.0, 249 μM for mGlu 4 , mGlu 8 , mGlu 6 and mGlu 7 receptors, respectively In Vivo L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction. Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats. Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rats.Dosage: 5-30 μg. Administration: Intrathecal inhection 4-5 days. Result: Dose-dependently increased paw withdrawal threshold. Form:Solid IC50& Target:mGlu 4 0.13 μM (EC 50 ) mGlu8 0.29 μM (EC 50 ) mGlu 6 1.0 μM (EC 50 ) mGlu7 249 μM (EC 50 )